Home / Vagitocin® / Vaginal atrophy

Vaginal atrophy

In conjunction with the menopause, many women develop vaginal atrophy. It is the decreasing estogen levels occuring during menopause that results in vaginal atrophy, as estrogen stimulates the growth of the mucosa.

Symptoms such as vaginal dryness, irritation and itching are common in women with vaginal atrophy. The risk of developing infection is increased and sexual intercourse can be painful which affects sex life negatively.

Frequently these problems can be improved by means of estrogen treatment in the form of tablets, patches or local treatment with creams or vaginal inserts. However, not all women can or are willing to use estrogen. PEPTONIC’s Vagitocin ® , which contains oxytocin, offers an alternative to estrogen.

Treatment with Vagitocin®

The reduction of the number of cell layers and the lack of mature cells in the vaginal mucous membrane during and after menopause.

A short term treatment with Vagitocin® can increase the number of cell layers and the number of mature cells in the vaginal mucosa.


Kerstin Uvnäs Moberg and Oxytocin

Kerstin_UvnasMoberg_200px Kerstin Uvnäs Moberg is the person behind the oxytocin research that is the foundation of PEPTONIC medical's products. Kerstin speaks on oxytocin » Book-on-Oxytocin New book on Oxytocin by Prof. Kerstin Uvnäs Moberg released »  

Subscribe for press releases

Would you like to receive press releases and news from PEPTONIC Medical straight to your email? Register for our newsletter service on aktietorget.se.

Subscribe for press releases and news »